PAM Variants and GLP‑1 Resistance
- A Stanford analysis identified PAM enzyme variants linked to reduced GLP‑1 drug response in some people. (x.com) - The variants p.S539W and p.D563G appeared in roughly one in ten people and associated with lower HbA1c success. (x.com) - This could explain why the same GLP‑1 dose works for some patients but not others, prompting calls for genetics‑informed prescribing. (x.com)
About one in ten people carry PAM gene variants that blunt response to GLP‑1 diabetes drugs, Stanford researchers report. (news.stanford.edu) PAM encodes the enzyme peptidyl‑glycine alpha‑amidating monooxygenase, which chemically “activates” peptide hormones by amidation. (pmc.ncbi.nlm.nih.gov) GLP‑1 (glucagon‑like peptide‑1) is an amidated incretin that raises post‑meal insulin release and slows gastric emptying to lower blood glucose. (pmc.ncbi.nlm.nih.gov) The international study, led by Anna Gloyn and published in Genome Medicine on March 29, 2026, meta‑analysed three cohorts (IMI‑DIRECT, GoDARTS, PRIBA) and 1,119 people treated with GLP‑1 receptor agonists. (link.springer.com) The team focused on two hypomorphic PAM alleles, p.S539W and p.D563G, which reduced serum PAM amidation activity by about 52% and 20%, respectively. (link.springer.com) Clinically, p.S539W carriers had smaller HbA1c drops after six months of GLP‑1 therapy (−0.69% vs −1.24% in non‑carriers) and only 11.5% reached HbA1c <7% versus 25.3% of non‑carriers. (link.springer.com) Mechanistic tests showed carriers and whole‑body Pam knockout mice had higher circulating GLP‑1 but reduced GLP‑1 sensitivity (an 18% reduction in p.S539W carriers), plus accelerated gastric emptying that did not respond to exendin‑4. (pmc.ncbi.nlm.nih.gov) Population data put the combined carrier rate at roughly 10%, with the p.S539W minor allele frequency about 1% and p.D563G about 5% in previous datasets. (news.stanford.edu) (medrxiv.org) More than a quarter of people with type 2 diabetes now take GLP‑1 receptor agonists, and the authors say genotype‑guided prescribing could identify likely non‑responders earlier. (news.stanford.edu) The study does not yet show whether these PAM variants change weight‑loss outcomes at the higher GLP‑1 doses used for obesity, and the authors call for further clinical validation. (link.springer.com) “In some of the trials, we saw that individuals who had those variants were unable to lower their blood glucose levels as effectively after six months of treatment,” Anna Gloyn said — a finding the team says could steer future precision prescribing studies. (news.stanford.edu)
